hypoxia; skeletal muscle blood flow UNDER CONDITIONS of systemic hypoxia (decreased oxygen availability) and during exercise (increased demand) there is a need for an increase in blood flow. The combination of these conditions produces a compensatory vasodilation relative to the same level of exercise under normoxic conditions and greater than that predicted by a simple summation of the individual responses (3, 5, 6, 21, 23, 31, 32) . The compensatory vasodilation during hypoxic exercise occurs to ensure an adequate oxygen delivery to the active muscles.
The factors responsible for the compensatory vasodilation, as well as their interactions, remain unclear. Previous studies have demonstrated that ␤-adrenergic receptor activation is responsible for a substantial portion of the hypoxic vasodilation at rest (2, 29, 31) and during mild forearm exercise (31) . However, the ␤-adrenergic component of the compensatory vasodilation decreases with increased exercise intensity. A portion of the ␤-adrenergic receptor-mediated hypoxic vasodilation at rest occurs through a nitric oxide (NO) pathway (29) . Along these lines, we recently demonstrated (5) that NO contributes to the compensatory vasodilation at rest and during mild-and moderate-intensity hypoxic exercise. However, the ␤-adrenergic receptor portion of this NO component has yet to be examined directly during hypoxic exercise. Thus the aim of the present study was to investigate the interaction between ␤-adrenergic receptors and NO-mediated skeletal muscle vasodilation during hypoxic exercise. We hypothesized that NOmediated vasodilation becomes independent of ␤-adrenergic receptor activation with increased exercise intensity during hypoxic exercise.
METHODS

Subjects
A total of 17 young healthy Caucasian subjects (13 men and 4 women) volunteered to participate in two separate protocols (11 in protocol 1; 6 in protocol 2). Subjects gave written informed consent, were healthy, nonobese nonsmokers, and were not taking any medications (except for oral contraceptives in some women). Studies were performed after an overnight fast and with subjects refraining from exercise and caffeine for at least 24 h. Female subjects were studied during the early follicular phase of the menstrual cycle or the placebo phase of oral contraceptives (18, 19) . All protocols were approved by the Institutional Review Board and were performed according to the Declaration of Helsinki.
Forearm Exercise
Subjects performed rhythmic forearm exercise with a handgrip device, using the nondominant arm at 10% and 20% of each subject's maximal voluntary contraction (MVC; mean 47 Ϯ 3 kg, range 22-62 kg). The weight was lifted 4 -5 cm over a pulley at a duty cycle of 1-s contraction and 2-s relaxation (20 contractions/min); a metronome was used to ensure correct timing. The average weight used for forearm exercise in protocol 1 was 4.5 Ϯ 0.4 kg and 9.0 Ϯ 0.9 kg for 10% and 20% MVC, respectively. The average weight used for forearm exercise in protocol 2 was 5.5 Ϯ 0.2 kg and 10.9 Ϯ 0.4 kg for 10% and 20% MVC, respectively.
Heart Rate and Systemic Blood Pressure
Heart rate was recorded via continuous three-lead ECG. In protocol 1, systemic blood pressure was recorded via a brachial arterial catheter. In protocol 2, systemic blood pressure was assessed (beat to beat) with a finger plethysmograph (Finometer) on the nonexercising arm.
Arterial and Venous Catheterization
A 20-gauge, 5-cm catheter was placed in the brachial artery of the exercising arm under aseptic conditions after local anesthesia (2% lidocaine). The catheter was connected to a three-port connector in series (7) . One port was linked to a pressure transducer positioned at heart level (model PX600F, Edwards Lifescience, Irvine, CA) to allow measurement of arterial pressure and was continuously flushed (3 ml/h) with heparinized saline with a stopcock system to enable arterial blood sampling. The remaining ports allowed arterial drug administration. Deep venous blood was sampled via an 18-gauge, 3-cm catheter inserted retrograde in an antecubital vein (16) .
Forearm Blood Flow
Brachial artery mean blood velocity and diameter were determined with a 12-MHz linear-array Doppler probe (model M12L, Vivid 7, General Electric, Milwaukee, WI). Brachial artery blood velocity was measured with a probe insonation angle previously calibrated to 60°. Brachial artery diameter measurements were obtained at end diastole between contractions during steady-state conditions. Forearm blood flow (FBF) was calculated as the product of mean blood velocity (cm/s) and brachial artery cross-sectional area (cm 2 ) and expressed as milliliters per minute. Mean blood velocity measurements included the velocity profiles across the entire duty cycle (both contraction and relaxation phases).
Systemic Hypoxia
A self-regulating partial rebreathe system that clamps end-tidal CO2 at baseline levels despite large changes in minute ventilation was used to generate hypoxic conditions (1, 29, 31, 32) . The target arterial O 2 saturation (SO2; assessed via pulse oximetry) was ϳ80%. End-tidal carbon dioxide concentrations were monitored (Cardiocap/5, DatexOhmeda, Louisville, CO), and ventilation was assessed via a turbine (model VMM-2a, Interface Associates, Laguna Niguel, CA).
Pharmacological Infusions
Propranolol, a nonselective ␤-adrenergic receptor antagonist, was infused at a loading dose of 20 g·dl forearm volume Ϫ1 ·min Ϫ1 for 5 min followed by a continuous maintenance dose (25 g/min) . This dose blocks the forearm vasodilation to the ␤-adrenergic receptor agonist isoproterenol (isoprenaline) (10, 15) . N G -monomethyl-L-arginine [L-NMMA; nitric oxide synthase (NOS) inhibitor; Bachem] was infused at a loading dose of 5 mg/min for 5 min and then at a maintenance dose of 1 mg/min. This dose of L-NMMA has been shown to attenuate the forearm vasodilator response to exogenous acetylcholine (4, 5) .
Blood Gas and Catecholamine Analysis
Brachial artery and deep venous blood samples were analyzed with a clinical blood gas analyzer (Bayer 855 Automatic Blood Gas System, Boston, MA) for partial pressures of O 2 and CO2 (PO2 and PCO2), pH, and SO2. Arterial and venous O2 content were calculated with the measured PO2 and SO2 values. Arterial and venous plasma catecholamine (epinephrine and norepinephrine) levels were determined by HPLC with electrochemical detection.
Experimental Design
This study consisted of two experimental protocols. Protocol 1 was performed to investigate the interaction between ␤-adrenergic receptors and NO-mediated skeletal muscle vasodilation during hypoxic exercise. Each subject completed a resting baseline condition followed by rhythmic forearm exercise at 10% MVC, which was immediately increased to 20% MVC during normoxia and normocapnic hypoxia. Exposure to normoxia or hypoxia was alternated and randomized. Resting baseline and each exercise intensity (normoxia and hypoxia) were performed during a propranolol-only infusion followed by infusion of combined propranolol and L-NMMA (Fig. 1) . Because of the long half-life of L-NMMA, study drugs were always administered in the same order. A rest period of at least 20 min was allowed between conditions during each drug infusion. During each infusion (propranolol or propranolol-L-NMMA) and each condition (normoxia and hypoxia) arterial and venous blood was sampled at rest and at steady-state exercise for blood gas analysis and plasma catecholamine determination. Protocol 2 was performed to determine the reproducibility of the FBF and vasodilator response to hypoxic exercise. The exact same design was used in protocol 2, with the exception that study drugs were not administered and blood samples were not collected.
Data Analysis and Statistics
Data were collected at 200 Hz and analyzed off-line with signal processing software (WinDaq, DATAQ Instruments, Akron, OH). Mean arterial pressure (MAP) was determined from the brachial artery pressure waveform, and heart rate was determined from the electrocardiogram. Ventilation, end-tidal CO 2, and SO2 (pulse oximetry) were determined by averaging minutes 4 and 5 at rest and during each exercise intensity. FBF and arterial pressure were determined by averaging values from the fourth minute at rest and during each jap.physiology.org exercise bout. Forearm vascular conductance (FVC) was calculated as (FBF/MAP) ϫ 100 and expressed as millimeters per minute per 100 mmHg. The change (⌬) in FBF and FVC due to hypoxia at rest and due to hypoxic exercise (10% and 20% MVC) was calculated by subtracting resting FBF and FVC during normoxia at each drug infusion (propranolol or combined propranolol-L-NMMA) from FBF and FVC values obtained during hypoxia (at rest and during exercise) within each drug infusion. Blood gas and catecholamine values were determined from blood samples obtained during normoxia and hypoxia with each drug infusion. Arteriovenous oxygen difference during forearm exercise was calculated from the blood samples. Venoarterial (v-a) norepinephrine difference was calculated by the difference between venous and arterial norepinephrine concentrations.
All values are expressed as means Ϯ SE. To determine the effect of hypoxia with each treatment, differences in absolute FBF and FVC at rest (normoxia and hypoxia) and differences in ⌬FBF and ⌬FVC at rest and during each exercise intensity (normoxia and hypoxia) were determined via three-way ANOVA with repeated measures (protocol 1). Hemodynamic and respiratory parameters, blood gases, and catecholamines were compared via three-way ANOVA with repeated measures to test for differences with hypoxia at rest and during exercise across pharmacological infusions. Tukey post hoc analysis determined where statistical differences occurred. Statistical difference was set a priori at P Ͻ 0.05. To further explore the contribution of the ␤-adrenergic receptors and NO in the compensatory vasodilator response to hypoxic exercise, we compared via two-way ANOVA the difference in ⌬FVC (% change compared with respective normoxic exercise trial) between the following conditions: 1) control (saline), 2) L-NMMA alone, 3) propranolol alone, and 4) combined propranolol-L-NMMA. The saline and L-NMMA conditions were from our previously published work (5). Reproducibility was assessed via coefficients of variation and repeated-measures ANOVA (protocol 2).
RESULTS
Ten (7 men; 3 women) of the 11 subjects completed protocol 1. One subject did not complete the protocol because of symptoms of vasovagal syncope during hypoxia and was excluded from the analysis. Those subjects completing the study were 23 Ϯ 1 yr of age and 179 Ϯ 3 cm in height and weighed 74 Ϯ 5 kg [body mass index (BMI): 23 Ϯ 1 kg/m 2 ]. Six male subjects completed protocol 2. The subjects were 26 Ϯ 2 yr of age and 181 Ϯ 2 cm in height and weighed 82 Ϯ 3 kg (BMI: 25 Ϯ 1 kg/m 2 ).
Protocol 1
Systemic hemodynamic and respiratory responses. The group data (means Ϯ SE) for hemodynamic and respiratory responses due to combined forearm exercise and hypoxia with each drug infusion are presented in Table 1 . As expected, during both protocols heart rate and minute ventilation increased as a consequence of systemic hypoxia and incremental forearm exercise. Despite the elevated heart rate, MAP was similar during normoxia and hypoxia independent of drug infusion at rest and incremental exercise. By design, end-tidal CO 2 was maintained during all conditions.
Forearm exercise. Table 2 shows (means Ϯ SE) forearm hemodynamics at rest and with increasing exercise intensity during propranolol and combined propranolol-L-NMMA. The absolute FBF and FVC as well as the ⌬FBF and ⌬FVC during incremental hypoxic exercise were higher compared with normoxic exercise of the same intensity during the propranolol infusion (main effect of hypoxia, P Ͻ 0.05; Table 2 ). Combined propranolol-L-NMMA administration decreased baseline resting blood flow and conductance under normoxic and hypoxic conditions compared with values observed during propranolol alone (P Ͻ 0.05; Table 2 ). However, ⌬FBF (9.9 Ϯ 3.2 vs. 9.3 Ϯ 3.2 ml/min, P ϭ 0.14) and ⌬FVC (9.3 Ϯ 3.9 vs. 8.7 Ϯ 2.7 ml·min Ϫ1 ·100 mmHg
Ϫ1
, P ϭ 0.37) due to acute systemic hypoxia at rest did not differ between propranolol alone and combined propranolol-L-NMMA infusion.
Although the combined infusion of propranolol and L-NMMA reduced absolute FBF and FVC with exercise at 10% and 20% MVC under normoxic conditions (P Ͻ 0.01; Table 2), the ⌬FBF or ⌬FVC was not statistically different between propranolol-alone and propranolol-L-NMMA infusion (P ϭ 0.51-0.63 for ⌬FBF; P ϭ 0.15-0.21 for ⌬FVC; Fig. 2 ). During hypoxic exercise, the absolute FBF and FVC were lower at 10% and 20% MVC during combined propranolol-L-NMMA infusions compared with propranolol alone (Table 2) . However, the combination of propranolol and L-NMMA only decreased ⌬FBF and ⌬FVC due to incremental hypoxic exercise at 20% MVC (P Ͻ 0.01; Fig. 2 ).
Relative contributions of ␤-adrenergic receptors and NO in compensatory vasodilator responses to hypoxic exercise. To gain a better understanding of the interaction between ␤-adrenergic receptors and NO-mediated skeletal muscle vasodilation during hypoxic exercise, we compared the present results (propranolol alone and combined propranolol-L-NMMA) with our previously published work (saline and L-NMMA alone) (5) . The compensatory vasodilator responses to hypoxic exercise at 10% MVC (% increase in ⌬FVC compared with respective normoxic exercise trial) were statistically identical during propranolol alone, L-NMMA alone, and combined propranolol-L-NMMA. However, at 20% MVC L-NMMA-alone and combined propranolol-L-NMMA infusions reduced the compensatory vasodilation compared with the propranololalone trials (P Ͻ 0.05) (Fig. 3) .
Blood gases. Hypoxia reduced arterial PO 2 (P Ͻ 0.05) and oxygen content (P Ͻ 0.05) at rest and with incremental forearm exercise during both drug trials (propranolol or propranolol-L-NMMA) ( Table 3) . Hypoxia also decreased venous oxygen content during propranolol alone (P Ͻ 0.05). Under each drug infusion the lower arterial oxygen content during hypoxia led to a lower arteriovenous oxygen difference compared with normoxic exercise (P Ͻ 0.05). Forearm oxygen consumption increased similarly with normoxic and hypoxic exercise at 10% and 20% MVC during propranolol infusion (Table 3) . During combined propranolol-L-NMMA, forearm oxygen consumption also increased with normoxic and hy- poxic exercise at 10% and 20% MVC (Table 3) . However, forearm oxygen consumption during normoxic and hypoxic exercise (10 and 20% MVC) was lower with combined propranolol-L-NMMA infusions compared with propranolol. Catecholamines. Hypoxia increased arterial epinephrine during propranolol and combined propranolol-L-NMMA infusions (P Ͻ 0.05) ( Table 4 ). There was a further increase in arterial epinephrine with incremental exercise under hypoxic conditions for both drug conditions (P Ͻ 0.05). Venous epinephrine during exercise (10 and 20% MVC) was substantially greater during hypoxia compared with normoxia (P Ͻ 0.05). Additionally, systemic hypoxia only increased v-a norepinephrine difference at rest during combined propranolol-L-NMMA administration (P Ͻ 0.05).
Protocol 2
The reproducibility of the FBF and vasodilator responses to normoxic and hypoxic exercise are presented in Table 5 . Resting FBF and FVC during both normoxic and hypoxic trials were highly reproducible and not different between trials 1 and 2 for each respective condition. Similarly, FBF and FVC were reproducible during the normoxic exercise trials. Of particular interest to the present study, FBF and FVC were not different between hypoxic exercise trials (for both 10% and 20% MVC) and demonstrated highly reproducible values for all subjects (intraindividual coefficient of variation ranged from 2.8% to 5.5%).
DISCUSSION
The primary novel finding of this study is that the NOmediated component of the compensatory vasodilation during hypoxic exercise is regulated through different pathways with increasing exercise intensity. These findings are supported by the significant reduction in ⌬FBF and ⌬FVC with combined inhibition of ␤-adrenergic receptors (propranolol) and NOS (L-NMMA) during hypoxic exercise at 20% MVC and a lack of change at 10% MVC compared with propranolol alone (Fig. 2) . Previous findings from our group have demonstrated that NO-mediated mechanisms contribute to the compensatory vasodilation during forearm exercise at 10 and 20% MVC (5) and that ␤-adrenergic receptor activation is responsible for a portion of the response during forearm exercise at 10% MVC (31) . When the present results are integrated with our previously published work (5), they suggest that 1) at lower-intensity forearm exercise (10% MVC) NO contributes to the compensatory vasodilation via ␤-adrenergic receptor activation and 2) at higher-intensity exercise the contribution of NO becomes independent of the ␤-adrenergic receptors. The contribution of each of these pathways and their interactions are demonstrated in Fig. 3 . Additionally, protocol 2 confirms that the compensatory vasodilator response to hypoxic exercise is highly reproducible between trials, and therefore the reductions in FBF and FVC at 20% MVC following combined administration of L-NMMA and propranolol found in protocol 1 are not influenced by bout order.
To our knowledge this is the first study to examine the interaction between ␤-adrenergic receptors and NO-mediated skeletal muscle vasodilation during hypoxic exercise. Results from the present study (Table 4 ) and previous reports (31, 32) demonstrate a graded release of epinephrine with incremental hypoxic forearm exercise. In turn, we have also demonstrated an important contribution of enhanced systemic epinephrine release as a signal for vasodilation under hypoxic conditions at rest and during hypoxic exercise (29, 31) . The comparison and integration of our present results with our previously published work (5) suggest that this involves ␤-adrenergic receptor activation via a NO pathway at lower-intensity hypoxic forearm exercise (Fig. 3) . However, an alternative stimulus for NOmediated vasodilation occurs with higher exercise intensity.
Potential Stimuli for NO Release During Hypoxic Exercise
Previous work in our lab (5, 6) suggests that adenosine receptor activation is not a major source of NO production during hypoxic exercise. Other potential sources may include, but are not limited to, prostaglandins and ATP (13, 20, 25, 26) . Since ATP is released from erythrocytes with hemoglobin desaturation (i.e., hypoxia) and mechanical deformation (i.e., exercise) (14, 27, 28) and venous plasma levels of ATP are elevated during hypoxic exercise compared with normoxic exercise (13) an ATP/NO-mediated component to the compensatory vasodilation remains an attractive hypothesis. Mechanistically, ATP can induce vasodilation by binding to the purinergic P 2y receptors located on vascular endothelial cells, causing them to release NO, prostaglandins, and/or endotheliumderived hyperpolarizing factor (EDHF) (11, 17, 22, 30) . Consequently, it is possible that ATP contributes to the NOmediated compensatory vasodilation during hypoxic exercise. It should be noted that significant hypoxic compensatory vasodilation persists (compared with respective normoxic condition) under ␤-adrenergic receptor blockade and NOS inhibition at lower-intensity exercise, thus demonstrating that other mechanisms participate in the compensatory vasodilation during mild exercise. By contrast, the compensatory vasodilation during heavier hypoxic exercise is nearly abolished after NOS inhibition (5) and is influenced minimally by ␤-adrenergic receptor activation (Fig. 3) . Taken together, these findings suggest that, as exercise intensity increases, NO is the final common pathway for the compensatory dilator response during hypoxic exercise. However, the stimulus for NO release varies with increasing intensity of muscle contraction.
Experimental Considerations
There are four potential limitations to our study that should be mentioned. First, the present study was designed to investigate the interaction between ␤-adrenergic receptors and NOmediated skeletal muscle vasodilation during hypoxic exercise without concurrent ␣-adrenergic blockade. In contrast, our previous conclusions that ␤-adrenergic receptor activation contributes to hypoxia-mediated vasodilation during mild (10% MVC) exercise were based on studies performed against a background of ␣-adrenergic blockade (31) . Since there is potential for enhanced presynaptic catecholamine release during ␣-adrenergic blockade (24) and it is possible that norepinephrine-mediated ␤-receptor activation exists when ␣-receptors are blocked, the contribution of ␤-adrenergic receptormediated vasodilation could have been overestimated in our previous study. However, this was likely not the case, for reasons previously discussed in detail (31) .
Second, there is evidence that variation in the ␤ 2 -receptor gene contributes to interindividual differences in vascular responses to stimulation of ␤ 2 -adrenergic receptor and appears to be dependent on differences in endothelial generation of NO (12) . In this context, individuals homozygous for the Gly16 ϩ Glu27 variant demonstrate significantly greater blood flow responses to locally infused isoproterenol than individuals homozygous for the Arg16 ϩ Gln27 variant (8, 12) . ␤ 2 -Receptor genotype was not determined in the present study or in any of our previous studies related to the vasodilator responses to hypoxic exercise (5, 31) . Therefore, we cannot be certain that the subjects in the present study would display the same ␤ 2 -adrenergic receptor-mediated and NO-mediated components of the compensatory vasodilation during hypoxic forearm exercise as seen in our previous subjects (5, 31) . However, the allelic frequency for Gly16 ϩ Glu27 in Caucasians is rare (9) , and therefore our studies, in which subjects were randomly recruited, likely consisted of similar numbers of each ␤ 2 -receptor variant.
Third, the lack of a trial involving NOS inhibition alone (via L-NMMA) may limit our interpretation of the interactions between ␤-adrenergic receptors and NO in the regulation of vascular tone during hypoxic exercise. However, because of the complex nature and length (5-6 h) of these experiments, we chose not to include a third drug condition and extend the duration of our study to 8 -9 h. We have previously demonstrated that ␤-adrenergic mechanisms contribute to the compensatory vasodilation during mild hypoxic exercise (31) and that NO is also obligatory to this response during mild and heavier forearm exercise (5) . Therefore, our goal was to examine the extent to which the NO-mediated vasodilation is independent of ␤-adrenergic activation during heavier exercise. The results of the present study and those of our previous study (5) together suggest that NO contributes to the compensatory vasodilation across increasing levels of forearm exercise. However, ␤-adrenergic receptor activation appears to only contribute to the NO-mediated mechanisms at lowerintensity exercise. Thus the NO-mediated component of the compensatory vasodilation during hypoxic exercise is regulated through different pathways with increasing exercise intensity.
Fourth, in the present study forearm oxygen consumption during normoxic and hypoxic exercise was lower with combined propranolol-L-NMMA infusions compared with propranolol alone. This difference is likely attributed to the use of deep forearm venous sampling used to calculate arteriovenous O 2 difference. Along these lines, the venous drainage of the forearm can be anatomically complex, and samples may not always reflect primarily venous blood from the contracting forearm muscles. Additionally, the distribution of forearm flow may have been different between conditions.
Conclusions
The source of the NO contributing to compensatory dilation becomes less dependent on ␤-adrenergic mechanisms as exercise intensity increases. Identifying other potential sources for NO and determining how they interact during moderate and heavy hypoxic exercise warrants further study.
